These promising alternatives include: For people with immunodeficiencies, subcutaneous immunoglobulin (SCIg) may be a suitable alternative. This involves injecting purified immunoglobulin into the ...

"Moving to IVIG before the infections start makes much more sense." Banerjee also commented that, in general, "the myeloma field has been moving from IV treatments to subcutaneous treatments to ...

(Bloomberg) -- Australian biotech group CSL Ltd. has begun enrolling US patients in a late-stage study to test a self-administered antibody-based therapy for a blood circulation issue that’s one ...

Decades into its tenure as a drug seller, CSL Behring has finally dipped its toe into the waters of TV advertising. | Decades ...

This medication may rarely cause serious problems from blood clots (such as heart attack, stroke, blood clots in the lungs or legs). You may be at increased risk for blood clots if you are an ...

† Total IgG levels reflected trough values on IVIg therapy and steady state during SCIg therapy. ‡ Mean values from three laboratory draws over 19 months. AE: Adverse event; HA: Headache; Ig ...

Finally, subcutaneous immunoglobulin (SCIG), an immunoglobulin treatment administered under the skin, is an alternative treatment you could consider. SCIG can be administered at home and uses a ...

Furthermore, Subcutaneous Immunoglobulin (SCIg) is gaining traction in homecare settings, particularly for the geriatric population and individuals with lifestyle-related illnesses. Meanwhile ...

HYQVIA is the first and only facilitated subcutaneous immunoglobulin (fSCIG) for CIDP, approved earlier this year by the U.S. Food and Drug Association (FDA) as maintenance therapy in adults with ...

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to SCIg without initial intravenous ...

has approved an expanded label for XEMBIFY ®, the company’s 20% subcutaneous immunoglobulin (SCIg), to include treatment-naïve patients with primary humoral immunodeficiencies (PI).